Emerald Advisers’s Edwards Lifesciences EW Stock Holding History

Emerald Advisers’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,577	Closed	-$528K	–	253
2019 Q2	$528K	Sell	8,577 -4,227	-33%	-$256K	0.02%	184
2019 Q1	$817K	Sell	12,804 -69	-0.5%	-$3.94K	0.03%	183
2018 Q4	$657K	Sell	12,873 -6,699	-34%	-$339K	0.03%	177
2018 Q3	$1.14M	Sell	19,572 -699	-3%	-$34.2K	0.04%	169
2018 Q2	$984K	Sell	20,271 -654	-3%	-$30.5K	0.04%	183
2018 Q1	$973K	Sell	20,925 -2,124	-9%	-$92.2K	0.04%	185
2017 Q4	$866K	Sell	23,049 -1,245	-5%	-$45.7K	0.03%	185
2017 Q3	$885K	Buy	24,294 +8,604	+55%	+$328K	0.04%	181
2017 Q2	$618K	Sell	15,690 -8,403	-35%	-$307K	0.03%	188
2017 Q1	$755K	Hold	24,093	–	–	0.03%	194
2016 Q4	$753K	Sell	24,093 -480	-2%	-$15.6K	0.03%	194
2016 Q3	$988K	Hold	24,573	–	–	0.04%	240
2016 Q2	$817K	Buy	+24,573	New	+$841K	0.04%	262

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Emerald Advisers's EW Position: Q3 2019 in Review

Emerald Advisers sold out of Edwards Lifesciences (EW) in Q3 2019, closing a stake of 8,577 shares — an estimated $528K sold.

Emerald Advisers first reported a position in EW in Q2 2016 and held it in 13 quarters. The position peaked at $1.14M in Q3 2018. 965 funds tracked by Wall St. Rank hold EW as of Q3 2019.

Emerald Advisers reported no remaining Edwards Lifesciences position as of Q3 2019 after selling out during the quarter.
Emerald Advisers sold 8,577 Edwards Lifesciences shares in Q3 2019, an estimated $528K.
Emerald Advisers first reported a position in Edwards Lifesciences in Q2 2016 and held it in 13 quarters.
Emerald Advisers's Edwards Lifesciences position peaked at $1.14M in Q3 2018.
965 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2019.

Based on Emerald Advisers's 13F filing for Q3 2019, filed 31 Oct 2019.